National Cancer Institute



Director's Update

U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health



Director, National Cancer Institute

National Cancer Advisory Board 6, 2007

February

Director's Update

- Budget Update: 2007 and 2008
- President Bush's Visit to NIH
- •NIH Reform Act of 2006
- Reorganization of the NCI
 Office of the Director
- Clinical Trials Advisory Committee

FY 2007 President's Budget Development

(dollars in thousands)

FY 2006 obligations	\$4,790,059
FY 2007 President's Budget	\$4,753,609
Difference '06 to '07	- \$36,450
Percent Change '06 to'07	- 0.8%

After we pay for mandated increases such as taps, utilities, Roadmap, etc., our deficit is ~\$122 million (-2.6%).

FY 2007 Operating Budget Development

- NCI Executive Committee Portfolio Review
 - Identified ~\$175 million of reductions and phase-outs
 - Created a pool of ~\$60 million
- EC created a list of new initiatives and previously reduced existing projects to be considered for funding from pool
 - EC members independently gave each item a priority score and recommended funding level
 - Scores were collected and items ranked
 - Prioritized list discussed by EC; adjustments made
 - Additional items on list will be considered if funds become available

FY 2007 Operating Budget Development

NIH Guidelines under a full year CR:

- No inflationary adjustments on non-competing grants
 - approximately 3% decrease from commitments of record for all grants
- NIH to award the same number of competing RPGs as awarded in FY 2005 (about 9,600) with particular emphasis on new investigators
- Average cost of competing RPGs same as FY 06

FY 2007 Budget

- January 31: House passed <u>Revised</u> <u>Continuing Appropriations Resolution</u> for the 2007 year
 - Bill provides \$28.9 billion for NIH: an increase of \$620 million over FY 2006
- February 15: Current Continuing Resolution expires

Revised Continuing Appropriations Resolution, 2007

- Sets the Common Fund (which includes the NIH Roadmap) in the NIH OD at \$483 million
 - increase of about \$150 million
- No specific increase to most ICs
 - ICs retain funds previously earmarked for the NIH Roadmap and funds that were transferred to CMS in FY 2006 (\$267 million total)
- NIH will also receive funds to partially pay for the 2007 COLA increases for Federal salaries

Revised Continuing Appropriations Resolution, 2007

	New \$	Transfers within NIH	Total adjustments
Common Fund			
Roadmap (PB 2007)	\$361	\$ 82	\$443
Junior Pioneer Awards	40		40
Total Common Fund	\$401	\$ 82	\$483
NIH OD Programs			
New Investigators	91		91
National Children's Study	58	11	69
New activities related to reauthorization bill	7		7
Total OD	\$156	\$ 11	\$167
Other			
NLM for NCBI	5		5
NCMHD	4		4
NCRR	34		34
HHS Transfers	20		20
Total Other	\$ 63		\$ 63
Total	\$620	\$ 93	\$713

(Dollars in millions)

Revised Continuing Appropriations Resolution, 2007

- NIH to fund 500 more RPGs
- NIH–wide: 1,500 awards to new investigators

-(FY05 = 1,458; FY06 = 1,363)

 ICs to use half of the money they retain from Roadmap to fund additional RPGs

Revised Continuing Appropriations Resolution, 2007 NCI Level

	FY 2006	FY 2007 Annualized CR	FY 2007 House	_
NCI (w/o Roadmap)	\$4,747,229	\$4,750,522	\$4,793,356	(+\$46,127)
CMS transfer	3,293		0	
Roadmap	42,834	42,834	0	_
Total	\$4,793,356	\$4,793,356	\$4,793,356	
(Dollars in	thousands)			

(Dollars III thousands)

NCI Research Project Grants

	FY 2006		FY 2007 Annualized CR		FY 2007 House (est.)	
	No.	Amount	No.	Amount	No.	Amount
Noncompeting	3,892	\$1,596,655	3,878	\$1,547,748	3,878	\$1,547,748
Admin. supplements		49,089		49,870		49,870
Competing	1,280	415,067	1,244	403,280	1,310	424,697
Total	5,172	\$2,060,811	5,122	\$2,000,898	5,188	\$2,022,315

Assumes that NIH will continue its current grant policies of reducing noncompeting awards 3% from the commitment of record and no increase in the average cost of competing RPGs.

(Dollars in thousands)

NCI Research Project Grants Competing

	FY 2006	FY 2007 Annualized CR	FY 2007 House (est.)
Average cost	\$324	\$324	\$324
R01 payline (percentile)	12th	11th	12th
Success rate	19.4%	18.0%	18.9%

Assumes that NIH will continue its current grant policies of reducing noncompeting awards 3% from the commitment of record and no increase in the average cost of competing RPGs.

(Dollars in thousands)


FY 2008 President's Budget

- NIH PB request is \$28.849 billion:
 \$232 million (0.8%) over the FY 2007
 Annualized CR
- NCI PB is \$4.782 billion: 0.2% lower (-\$9 million) than the FY 2007 Annualized CR

 NIH Roadmap increases by \$72 million to \$486 million


Director's Update


- Budget Update: 2007 and 2008
- President Bush's Visit to NIH
- NIH Reform Act of 2006
- Reorganization of the NCI Office of the Director
- Clinical Trials Advisory Committee








"I love coming to the NIH; it is an amazing place. It is an amazing place because it is full of decent, caring, smart people, all aiming to save lives."











Director's Update

Budget Update: 2007 and 2008
President Bush's Visit to NIH

•NIH Reform Act of 2006

- Reorganization of the NCI Office of the Director
- Clinical Trials Advisory
 Committee

NIH Reform Act of 2006

- Third omnibus reauthorization in NIH history (first in 14 years)
 - Signed by the President January 15, 2007



- Key provisions
 - Divisions of Program Coordination
 - Common Fund
 - Council of Councils
 - Scientific Management Review Board
 - Authorization of appropriations
 - Reorganization
 - Reporting

Office of Portfolio Analysis and Strategic Initiatives (OPASI)

- Alan M. Krensky, M.D., NIH Deputy Director for the Office of Portfolio Analysis and Strategic Initiatives (OPASI)
 - M.D., University of Pennsylvania, 1977
 - Served at the Stanford University School of Medicine as:
 - Professor of pediatrics
 - Chief of the Division of Immunology and Transplantation Biology
 - Assoc. Chair for Research in the Department of Pediatrics
 - Assoc. Dean for Children's Health



NIH Reform Act of 2006: Implementation

- Ad Hoc Working Group of the NIH Steering Committee
 - Chaired by NIH Deputy Director
 Dr. Raynard Kington
 - Conduct detailed analysis and propose plans for its implementation
 - Comprised of IC Directors and NIH OD leadership in legislation, policy, management, communications, extramural and intramural activities, budget, and the Office of the General Counsel




NIH Reform Act of 2006: Implementation Groups

- Jeremy Berg: Organization of Division of Program Coordination, Planning and Strategic Initiatives (DPCPSI); trans-NIH coordination/planning
- Richard Hodes: Coding
- Betsy Nabel: Establishment of Scientific Management Review Board (SMRB); reorganizations; registration fees
- John Niederhuber: Reporting
- Francis Collins: Foundation of the NIH
- Tony Fauci: Peer review; demonstration programs; research training authority
- Steve Katz: Director's Discretionary Fund; 1% transfer; Clinical and Translational Science Awards (CTSA)

Director's Update


- Budget Update: 2007 and 2008
 President Bush's Visit to NIH
 NIH Reform Act of 2006
- Reorganization of the NCI
 Office of the Director
- Clinical Trials Advisory Committee



Director's Update

- Budget Update: 2007 and 2008
- President Bush's Visit to NIH
- NIH Reform Act of 2006
- Reorganization of the NCI Office of the Director
- Clinical Trials Advisory
 Committee

NCI Federal Advisory Groups




Clinical Trials Advisory Committee

- Established in response to the Clinical Trials Working Group (CTWG) recommendations that an extramural oversight committee be formed to advise the NCI Director on clinical trials
- Chaired by NCI Director
- Members appointed by NCI Director
 - 10 members hold concurrent membership on NCAB, BSA, BSC, or DCLG
 - 14 members represent the broad clinical trials community


U.S. Clinical Trials Treatment Sites (# of Sites by State that Currently have Patients

Enrolled on an Open Trials)




Clinical Trials Infrastructure

- NCI's Clinical Trials Cooperative Group Program (the "Groups") is distinctive among NIH-supported clinical trials programs:
 - A clinical trials infrastructure that is continuously available to test new therapeutic strategies
 - -Consists of researchers at institutions affiliated with the Groups who jointly develop and conduct trials in multi-institutional settings across state boundaries
 - -Flexible research agenda allows change of strategy in response to changing scientific opportunities and new discoveries




Trans-NCI Programs



Clinical Imaging Program


- Research and service components
- Molecular/functional imaging, profiling & therapy
- Integrates 3-D high-resolution electron microscopy
- Industry partnership for technology development
- Imaging incorporated into the majority of clinical trials at NCI

Simian immunodeficiency virus in 3D



Sougrat, Bartesaghi, Bennett, Subramaniam (2007)

New technologies for imaging cancer cells



Interior of MNT-1 melanoma cell at 30 nm resolution

Sriram Subramaniam, CCR NCI/NIH

Stereo view of interior of MNT-1 melanoma cell

